title: Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading.
abstract: BACKGROUND
  Right ventricular (RV) dysfunction is associated with adverse outcomes in heart failure (HF). Mechanical unloading should be more effective than pharmacologic therapy to reduce RV afterload and improve RV function. We compared RV size and function after aggressive medical unloading therapy to that achieved in the same patients after 3 months of left ventricular assist device (LVAD) support.
  
  
  RESULTS
  We studied 20 patients who underwent isolated LVAD placement (9 pulsatile and 11 axial flow). Echocardiograms were performed after inpatient optimization with diuretic and inotropic therapy and compared with studies done after 3 months of LVAD support. After medical optimization right atrial pressure was 11 +/- 5 mm Hg, mean pulmonary artery pressure 36 +/- 11 mm Hg, pulmonary capillary wedge pressure 23 +/- 9 mm Hg, and cardiac index 2.0 +/- 0.6 L.min.m(2). Preoperatively, RV dysfunction was moderate (2.6 +/- 0.9 on a 0 to 4 scale), RV diameter at the base was 3.1 +/- 0.6 cm, and mid-RV was 3.5 +/- 0.6 cm. After median LVAD support of 123 days (92 to 170), RV size and global RV dysfunction (2.6 +/- 0.9) failed to improve, despite reduced RV afterload.
  
  
  CONCLUSIONS
  RV dysfunction seen on intensive medical therapy persisted after 3 months of LVAD unloading therapy. Selection of candidates for isolated LV support should anticipate persistence of RV dysfunction observed on inotropic therapy.
authors.affiliation: Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Maryse
authors.initials: M
authors.lastname: Palardy
authors.forename: Anju
authors.initials: A
authors.lastname: Nohria
authors.forename: Jose
authors.initials: J
authors.lastname: Rivero
authors.forename: Neal
authors.initials: N
authors.lastname: Lakdawala
authors.forename: Patricia
authors.initials: P
authors.lastname: Campbell
authors.forename: Mahoto
authors.initials: M
authors.lastname: Kato
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Griffin
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Smith
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Couper
authors.forename: Lynne W
authors.initials: LW
authors.lastname: Stevenson
authors.forename: Michael M
authors.initials: MM
authors.lastname: Givertz
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D004232:Diuretics / Q000008:administration & dosage*; D018619:Echocardiography, Doppler, Pulsed; D005260:Female; D005500:Follow-Up Studies; D006334:Heart Function Tests; D006353:Heart-Assist Devices; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011336:Probability; D011669:Pulmonary Wedge Pressure; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D018497:Ventricular Dysfunction, Right / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*
chemical_list: D002316:Cardiotonic Agents; D004232:Diuretics